Guidelines on the diagnosis and management of W aldenström macroglobulinaemia

s), 120, 438. Dojcinov, S.D., Venkataraman, G., Raffeld, M., Pittaluga, S. & Jaffe, E.S. (2010) EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. American Journal of Surgical Pathology, 34, 405–417. Dojcinov, S.D., Venkataraman, G., Pittaluga, S., Wlodarska, I., Schrager, J.A., Raffeld, M., Hills, R.K. & Jaffe, E.S. (2011) Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood, 117, 4726–4735. Facon, T., Brouillard, M., Duhamel, A., Morel, P., Simon, M., Jouet, J.P., Bauters, F. & Fenaux, P. (1993) Prognostic factors in Waldenstrom’s macroglobulinemia: a report of 167 cases. Journal of Clinical Oncology, 11, 1553–1558. Fahey, J.L., Barth, W.F. & Solomon, A. (1965) Serum hyperviscosity syndrome. Journal of the American Medical Association, 192, 464–467. Feyler, S., O’Connor, S.J., Rawstron, A.C., Subash, C., Ross, F.M., Pratt, G., Drayson, M.T., Ashcroft, J., Cook, G. & Owen, R.G. (2008) IgM myeloma: a rare entity characterized by a CD20CD56-CD117immunophenotype and the t (11;14). British Journal of Haematology, 140, 547–551. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Guideline a 2014 John Wiley & Sons Ltd 329 British Journal of Haematology, 2014, 165, 316–333 Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317–324. Gachard, N., Parrens, M., Soubeyran, I., Petit, B., Marfak, A., Rizzo, D., Devesa, M., Delage-Corre, M., Coste, V., Laforet, M.P., de Mascarel, A., Merlio, J.P., Bouabdhalla, K., Milpied, N., Soubeyran, P., Schmitt, A., Bordessoule, D., Cogne, M. & Feuillard, J. (2013) IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia, 27, 183–189. Garcia-Sanz, R., Montoto, S., Torrequebrada, A., de Coca, A.G., Petit, J., Sureda, A., RodriguezGarcia, J.A., Masso, P., Perez-Aliaga, A., Monteagudo, M.D., Navarro, I., Moreno, G., Toledo, C., Alonso, A., Besses, C., Besalduch, J., Jarque, I., Salama, P., Rivas, J.A., Navarro, B., Blade, J. & Miguel, J.F. (2001) Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. British Journal of Haematology, 115, 575–582. Gertz, M.A. (2012) Baby, it’s cold outside!. Blood, 119, 5943–5944. Gertz, M.A., Kyle, R.A. & Noel, P. (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom’s macroglobulinemia. Journal of Clinical Oncology, 11, 914–920. Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukaemia & Lymphoma, 45, 2047–2055. Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 Trial. British Journal of Haematology, 147, 677–680. Gertz, M.A., Reeder, C.B., Kyle, R.A. & Ansell, S.M. (2012) Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplantation, 47, 1147–1153. Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H. & Gertz, M.A.; Eastern Cooperative Oncology Group (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101, 2593–2598. Ghobrial, I.M., Xie, W., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Poon, T., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010a) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. American Journal of Hematology, 85, 670–674. Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010b) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology, 28, 1422–1428. Griffiths, R., Mikhael, J., Gleeson, M., Danese, M. & Dreyling, M. (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood, 118, 4808–4816. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164–1174. Herrinton, L.J. & Weiss, N.S. (1993) Incidence of Waldenstrom’s macroglobulinemia. Blood, 82, 3148–3150. Hultcrantz, M., Bjorkholm, M., Goldin, L., Turesson, I., Schulman, S., Landgren, O. & Kristinsson, S. (2012) Elevated risk of venous but not arterial thrombosis in Waldenstr€ om’s macroglobulinemia and lymphoplasmacytic lymphoma. Blood (ASH Annual Meeting Abstracts),